Sector News

Boehringer to acquire NBE-Therapeutics for $1.43bn

December 13, 2020
Life sciences

Boehringer Ingelheim has signed a binding agreement to acquire all shares of clinical-stage Swiss biotechnology company NBE-Therapeutics for a total of €1.18bn ($1.43bn) to enhance its cancer pipeline portfolio.

The deal also includes contingent clinical and regulatory milestones.

NBE-Therapeutics develops antibody-drug conjugates (ADC) and advances targeted cancer therapies obtained from its immune-stimulatory iADC platform.

The acquisition will give Boehringer access to an innovative platform that will be used to build an ADC portfolio, as well as develop potential combinations with assets from its cancer immunology portfolio.

NBE-Therapeutics lead compound and an anti-ROR1 ADC, NBE-002 is currently in Phase I clinical trials for triple-negative breast cancer and other solid tumours.

Boehringer Ingelheim Board of Managing Directors member Michel Pairet said: “NBE-Therapeutics’ iADC platform adds exceptional tumour targeting capabilities to our oncology portfolio.

“Together with our immune cell-targeting assets, this could enable new powerful combinations that will allow for efficacious and durable treatments for patients.”

This deal will enhance Boehringer’s focus on targeted cancer cell-directed therapies and adds to current capabilities in antigen discovery and antibody and T-cell engager technologies.

With the acquisition, NBE-Therapeutics will work as a new site within Boehringer’s R&D network from its campus in Basel.

NBE-Therapeutics CEO Bertrand Damour said: “We look forward to progressing NBE-002, our lead programme and best-in-class anti-ROR1 ADC, and to continuing the fight against cancer alongside Boehringer Ingelheim with its strong clinical development capabilities.”

The closing of the deal, subject to customary closing conditions, is anticipated in the first quarter of next year.

Boehringer also signed an agreement to acquire all the shares of German biotech company Labor Dr Merk & Kollegen to strengthen its cancer immunology programme.

by Pharmaceutical-Technology.com

Source: pharmaceutical-technology.com

Related News

July 31, 2021

Lonza positions collagen as “key” to future of joint health market

Life sciences

NutritionInsight speaks with Lindsey Toth, associate director of product management at DFS & Ingredients, Lonza Capsules & Health Ingredients.

July 31, 2021

Novo Holdings co-leads Hemab’s US$ 55M Series A to advance next generation therapeutics for bleeding and thrombosis disorders

Life sciences

The company was created in 2020 by Novo Seeds, which worked closely with the founders to develop a commercially attractive business plan to maximise the potential of Hemab’s promising technology platform.

July 31, 2021

BD acquires Tepha to drive new innovations in soft tissue repair and regeneration

Life sciences

BD (Becton, Dickinson and Company) announced today it has acquired Tepha, Inc., a leading developer and manufacturer of a proprietary resorbable polymer technology.

Send this to a friend